Tag: CTL019

March 30, 2017 Off

FDA accepts Novartis’s BLA for acute lymphoblastic leukemia treatment

By Dino Mustafić

US Food and Drug Administration (FDA) has accepted the Novertis’s Biologics License Application (BLA) filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL).